Singh, Gagandeep published the artcileSynthesis, molecular docking, α-glucosidase inhibition, and antioxidant activity studies of novel benzimidazole derivatives, SDS of cas: 4760-35-4, the publication is Medicinal Chemistry Research (2020), 29(10), 1846-1866, database is CAplus.
A novel series of N-methyl/benzyl-substituted benzimidazolyl-linked para-substituted benzyl-based compounds containing 2,4-thiazolidinediones, di-Me malonate (DMM) and di-Et malonate (DEM) were designed, docked, synthesized, and evaluated for their antidiabetic activity studies. Four targeted compounds I (R = Me, Bn) and II showed good inhibitory potential in the range of 4.10 +/- 0.01 to 9.12 +/- 0.06μM. Furthermore, synthesized compounds were evaluated for their antioxidant potential and compared with standard ascorbic acid and results showed that compound I (R = Bn) (EC50 = 0.176 +/- 0.002 mM) being the most active. Compounds I and II exhibited prominent antidiabetic as well as antioxidant activity. Compound I (R = Bn) was considered a promising candidate for this series. The designed mols. were docked into α-glucosidase protein (PDB Code. 3TOP) to develop a correlation with the α-glucosidase inhibition studies and were also addnl. docked into PPARγ proteins (PDB ID: 2PRG) with rosiglitazone (standard drug) to study their PPARγ binding affinity in comparison with rosiglitazone and to classify these compounds for their PPARγ agonistic behavior.
Medicinal Chemistry Research published new progress about 4760-35-4. 4760-35-4 belongs to imidazoles-derivatives, auxiliary class Chloride,Benzimidazole, name is 2-(Chloromethyl)-1-methyl-1H-benzo[d]imidazole, and the molecular formula is C25H29N9O3, SDS of cas: 4760-35-4.
Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem